By Bruce Buckley
Patients with a history of myocardial infarction (MI) and elevated high-sensitivity C-reactive protein (hs-CRP) who received quarterly injections of the interleukin-1 beta monoclonal antibody canakinumab were 15% less likely to have a major adverse cardiovascular event than the placebo group during the multinational CANTOS study.
The trial—presented at ESC Congress 2017, in Barcelona, Spain, and published in The New England Journal of Medicine (2017 Aug 27. doi: